GDNF is not required for catecholaminergic neuron survival in vivo
- 24 February 2015
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- Vol. 18 (3) , 319-322
Abstract
Glial cell line-derived neurotrophic factor (GDNF) is in clinical trials for treating Parkinson's disease. However, endogenous GDNF function in brain catecholaminergic neurons has remained controversial. The authors utilized three complementary conditional knock-out approaches during development and adulthood and found that GDNF is not required for the maintenance of the catecholaminergic neurons in mice.Keywords
This publication has 18 references indexed in Scilit:
- Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neuronsNeurobiology of Disease, 2012
- Priorities in Parkinson's disease researchNature Reviews Drug Discovery, 2011
- Tamoxifen-Independent Recombination in the RIP-CreER MousePLOS ONE, 2010
- Characterisation of behavioural and neurodegenerative changes induced by intranigral 6‐hydroxydopamine lesions in a mouse model of Parkinson’s diseaseEuropean Journal of Neuroscience, 2010
- Constitutive Ret Activity in Knock-In Multiple Endocrine Neoplasia Type B Mice Induces Profound Elevation of Brain Dopamine Concentration via Enhanced Synthesis and Increases the Number of TH-Positive Cells in the Substantia NigraJournal of Neuroscience, 2007
- Absence of Ret Signaling in Mice Causes Progressive and Late Degeneration of the Nigrostriatal SystemPLOS Biology, 2007
- RET Is Dispensable for Maintenance of Midbrain Dopaminergic Neurons in Adult MiceThe Journal of Neuroscience, 2006
- In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is alteredSynapse, 2006
- The GDNF family: Signalling, biological functions and therapeutic valueNature Reviews Neuroscience, 2002
- GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic NeuronsScience, 1993